Beijing 302 Hospital

• NCT07797894

  Phase 1/2, Not yet recruiting, 80 people, 1 Sept 2026

• NCT07514832

  Phase 2, Recruiting, 48 people, 7 Apr 2026

• Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS

  Phase 2, Recruiting, 40 people, 20 Nov 2025

• Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

  Phase 2, Recruiting, 50 people, 22 Jul 2025

• NCT06741722

  Phase 2, Recruiting, 20 people, 19 Dec 2024

• NCT06536959

  Phase 2, Recruiting, 67 people, 5 Aug 2024

• NCT06503796

  Phase 4, Not yet recruiting, 60 people, 16 Jul 2024

• NCT06418594

  Phase 2, Recruiting, 30 people, 17 May 2024

• NCT06416709

  Collaborator, Phase 1/2, Status unknown, 80 people, 16 May 2024

• NCT05362942

  Phase 2, Status unknown, 52 people, 5 May 2022

• NCT05012800

  Phase 4, Status unknown, 300 people, 19 Aug 2021

• NCT04285424

  Collaborator, Early phase 1, Status unknown, 30 people, 26 Feb 2020

• NCT04159142

  Collaborator, Phase 2, Recruiting, 414 people, 12 Nov 2019

• NCT04138719

  Collaborator, Phase 2, Recruiting, 520 people, 24 Oct 2019

• NCT02965911

  Phase 1/2, Withdrawn, 0 people, 17 Nov 2016

• NCT02555943

  Collaborator, Phase 2/3, Completed, 23 people, 22 Sept 2015

Sources: clinicaltrials.gov